Living Meta-Analysis and Open Data on MDMA Therapy for PTSD

Living Systematic Review Aggregates All MDMA-PTSD Trials

A newly released living systematic review and meta-analysis, published on October 11, 2026 (OpenAlex W7221434876), compiles all published randomized controlled trials (RCTs) of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD). This open-data resource, accessible via sypres.io, currently includes six RCTs with a combined 286 participants. All trials to date were sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), underscoring the field's reliance on a single funder and research group for initial evidence.

The resource applies inverse-variance random-effects meta-analysis to standardized mean differences in PTSD outcomes. MDMA-AT demonstrated a moderate reduction in PTSD symptoms compared to control (Hedges’ g = −0.71), with higher response (risk ratio [RR] = 1.35) and remission rates (RR = 2.25) than placebo. The living nature of the review means it will be updated as new studies emerge, offering a dynamic, transparent synthesis for researchers, clinicians, and policy stakeholders tracking this rapidly evolving field.

Mechanisms, Methodology, and Transparency

MDMA-assisted therapy combines pharmacological and psychotherapeutic interventions, with MDMA hypothesized to facilitate emotional processing and therapeutic alliance during trauma-focused psychotherapy. The living review's open-data approach allows independent reanalysis and meta-regression, including exploration of dosing variables and participant subgroups, which is particularly valuable as the field awaits larger, more diverse trials.

Transparency is enhanced by making raw trial data and meta-analytic code available, addressing long-standing calls for open science in psychedelic research. However, a non-obvious implication is that the resource also exposes the field's current limitations: all included studies are MAPS-sponsored, and most share similar protocols and populations, raising questions about generalizability and independence of results.

Policy, Regulatory, and Research Implications

The living meta-analysis arrives as regulators such as the U.S. Food and Drug Administration (FDA) and Health Canada weigh new drug applications for MDMA-AT in PTSD. The resource provides a single, up-to-date reference point for policymakers, health technology assessors, and guideline developers, who must evaluate both efficacy and certainty of evidence. The review's use of the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework assigned the current evidence a 'low certainty' rating, reflecting both methodological and external validity concerns.

For clinicians and health systems, the open dashboard supports evidence-based decision-making, but also underscores the need for caution: effect sizes are moderate, but the trials are small, short-term, and conducted in highly controlled settings. The living review can help identify emerging patterns—such as differential effects by trauma type or comorbidity—that static meta-analyses may miss. As new independent and larger-scale trials are launched, particularly outside the MAPS network, this resource will be critical for ongoing synthesis and rapid policy response.

Risks, Bias, and Evidence Limitations

Despite promising symptom reductions, the review highlights persistent risks and methodological challenges. Most studies were rated low risk of bias by Cochrane criteria, but the authors caution that these tools may not fully capture unique issues in psychedelic trials, such as functional unblinding, expectancy effects, and therapist allegiance. For example, participants and therapists often correctly guess treatment allocation due to MDMA's noticeable psychoactive effects, potentially inflating observed benefits.

Safety data remain limited, with short-term adverse events (e.g., transient anxiety, blood pressure elevation) reported but insufficient long-term follow-up to assess rare or delayed harms. The living review's open structure allows for continuous integration of new safety signals as they arise, but clinicians and policymakers should remain vigilant about the low certainty of current evidence and the possibility of publication bias, especially given the single-sponsor nature of the field to date.

Outlook: Awaiting Independent Trials and Regulatory Decisions

The open-data meta-analytic resource represents a significant advance for transparency and synthesis in psychedelic research, but the field remains at an inflection point. Key regulatory decisions are pending, and the evidence base is expected to expand with new, independently funded trials in the U.S., Europe, and Australia over the next two years. The living review will be instrumental in tracking these developments and updating effect estimates in real time.

For now, the moderate effect sizes and improved response rates reported by the review should be interpreted with caution given the low certainty of evidence and the lack of independent replication. As the field matures, the resource's greatest value may be in surfacing both positive and negative findings, helping stakeholders avoid overreliance on early, potentially biased data. The next phase of research will test whether MDMA-AT's promise holds up under broader, more rigorous scrutiny.

How we research: This article was written by Dr. Alex Morgan, PhD (Neuroscience, Policy Editor), and reviewed by Dr. Jamie Lin, MD, on 2026-10-14. All claims are sourced from primary trial registries, regulatory filings, and the published meta-analysis.